Anti-Lymphocyte-activation gene 3 (LAG-3) antagonists

These data indicate that LAG3 is a key bottleneck to successful PI3K delta-targeted immunotherapy and provide a rationale for combining PI3K deltaPI3/LAG3 blockade in future clinical studies (Lauder et al. 2020)

It appears that monotherapy is hardly effective and the combination with anti-PD-1 is poorly effective. A lot of trials are ongoing. (2021-07-21 )

However, First-line treatment with RELA+NIVO FDC demonstrated a statistically significant PFS benefit compared to NIVO monotherapy in patients with advanced melanoma. RELA+NIVO FDC was well tolerated with a manageable safety profile and without unexpected safety signals. This is the first phase III study of a novel FDC to demonstrate a clinically meaningful benefit by dual inhibition of the LAG-3 and PD-1 pathways (NCT03470922 Nivolumab + Relatlimab vs …